

19 August 2025

## EVE SUBMITS FIRST COMMERCIAL PURCHASE ORDER FOR LIBBO™

- First commercial purchase order submitted for Libbo™, EVE's proprietary oral dissolving film formulation for the treatment of erectile dysfunction.
- Manufactured to be undertaken by a GMP-certified pharmaceutical partner.
- In line with expectations for Libbo™ to be available for prescription before end-2025.
- Second significant milestone this quarter, following the first commercial PO for Dyspro™.
- No further regulatory steps are required before Libbo™ can be prescribed.
- Libbo™ offers a discreet, convenient, and fast-acting alternative to traditional ED treatments.
- Manufacturing commencing immediately, with shipment expected in Q4 2025.

**EVE Health Group Limited (ASX: EVE, EVE or the Company)** is pleased to announce that it has submitted the first commercial purchase order for Libbo™, the Company's proprietary oral dissolving film formulation utilising established active pharmaceutical ingredients (APIs) for the treatment of erectile dysfunction (ED).

The order has been placed with a very capable GMP-certified manufacturer. Manufacturing will commence immediately, with shipment to Australia expected in Q4 2025. This order is in line with EVE's expectations for Libbo to be available for prescription before the end of 2025 and represents the second significant milestone for the Company's pharmaceutical division this quarter, following the first commercial PO for Dyspro™.

### Path to Commercial Launch

Libbo represents EVE's first prescription pharmaceutical product in the men's health category and marks a significant operational milestone in the Company's pharmaceutical division.

No further regulatory steps are required to enable authorised prescribers within EVE's network to prescribe Libbo. Medical doctors who are TGA Authorised Prescribers already have TGA pre-approval to prescribe Dyspro and Libbo without delay.

## Market Opportunity

Erectile dysfunction is a prevalent condition affecting 1 in 5 men over the age of 18<sup>1</sup> and an estimated 40% of men over the age of 40<sup>2</sup>, with a significant impact on quality of life and mental health. The global ED treatment market is valued at over USD \$5.3 billion<sup>3</sup> and is forecast to grow steadily over the next decade, supported by increasing awareness, reduced stigma, and advances in delivery formats.

Libbo's oral dissolving film format offers patients a discreet, convenient, and fast-acting alternative to traditional tablets, potentially supporting higher compliance and patient satisfaction.

**Commenting on the milestone, Executive Director and Chief Scientific Officer Dr Stuart Gunzburg said:** "Placing our first commercial order for Libbo™ is a major step in delivering a high-quality, patient-friendly ED treatment to market. This product underscores our ability to develop and commercialise innovative pharmaceutical solutions and expands our prescription product portfolio into an important men's health segment."

Further updates will be provided as manufacturing progresses and commercial rollout preparations are finalised.

Authorised for release by the Board of Directors

— ENDS —

## Company enquiries

+61 8 6465 5500

info@evehealthgroup.com.au

## About EVE Health Group

EVE Health Group (ASX: EVE) is an Australian-based health company developing and commercialising evidence-based wellness and pharmaceutical products. Through its subsidiaries Meluka Australia and Nextract EVE delivers science-led innovations designed to support consumer and practitioner health across retail, pharmacy and clinical channels.

For further information, please visit [www.evehealthgroup.com.au](http://www.evehealthgroup.com.au) and follow us on LinkedIn.

---

<sup>1</sup> Prevalence and Risk Factors for Erectile Dysfunction in the US, *The American Journal of Medicine*, vol — (2006), [https://www.amjmed.com/article/S0002-9343\(06\)00689-9/fulltext](https://www.amjmed.com/article/S0002-9343(06)00689-9/fulltext)

<sup>2</sup> [https://www.singlecare.com/blog/news/erectile-dysfunction-statistics/?utm\\_source=chatgpt.com](https://www.singlecare.com/blog/news/erectile-dysfunction-statistics/?utm_source=chatgpt.com)

<sup>3</sup> Coherent Market Insights - <https://www.coherentmarketinsights.com/market-insight/erectile-dysfunction-market-200>